← Leaderboards
Alex A Adjei
Mayo Clinic Coll Of Medicine, Rochester
$13,436,633
Attributed
$14,909,848
Total exposure
18
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$14,909,848 · 18
By mechanism
P30$5,974,727 · 6
UM1$4,275,804 · 1
U01$1,967,556 · 1
R44$1,237,030 · 1
U10$1,139,600 · 1
K01$285,661 · 1
Top collaborators
- Rosa Maria Diaz3 shared
- Shashikant Lele2 shared
- Ellis G Levine2 shared
- Anurag Kishor Singh2 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Virginia M Miller$9,622,525
- Thomas E. Witzig$5,636,824
- Lewis R Roberts$8,981,499
- Rebecca S Bahn$5,415,200
- Stephen J Russell$9,318,537
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchResourcesDoctor Of PhilosophyGrantProgramsRoswell Park Cancer InstituteClinical TrialsResponseMonitorFundingCancer Center Support GrantMalignant NeoplasmsProtocols DocumentationBaseResource SharingSafetyClinical Trial Phase INeoplasm /Cancer ChemotherapyParticipantReportingResearch PersonnelClinical Trials Data Monitoring CommitteesHuman Therapy EvaluationResearch Study
Grant awards (62)
Experimental Therapeutics Program$98,369
P30 · FY2022 · CA · contact PI
Experimental Therapeutics Program$98,245
P30 · FY2021 · CA · contact PI
Experimental Therapeutics Program$100,687
P30 · FY2020 · CA · contact PI
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$950,045
R44 · FY2019 · CA
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis$667,474
UM1 · FY2019 · CA · contact PI
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$108,000
R44 · FY2019 · CA
Experimental Therapeutics Program$81,108
P30 · FY2019 · CA · contact PI
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis$76,986
UM1 · FY2019 · CA · contact PI
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis$1,900,619
UM1 · FY2018 · CA · contact PI
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$178,985
R44 · FY2018 · CA
Phase 2 Clinical Trials Program for Experimental Therapeutics Clinical Trials Network$912,510
UM1 · FY2016 · CA · contact PI
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis$718,215
UM1 · FY2016 · CA · contact PI
Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.$523,600
U10 · FY2015 · CA
Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.$616,000
U10 · FY2014 · CA
Clinical Research Services$330,902
P30 · FY2012 · CA · contact PI
Protocol-Specific Research Support$271,183
P30 · FY2012 · CA · contact PI
Protocol Review & Monitoring$190,802
P30 · FY2012 · CA · contact PI
Data & Safety Monitoring$128,930
P30 · FY2012 · CA · contact PI
Clinical Research Services$357,540
P30 · FY2011 · CA · contact PI
Protocol-Specific Research Support$293,011
P30 · FY2011 · CA · contact PI
Protocol Review & Monitoring$206,160
P30 · FY2011 · CA · contact PI
Data & Safety Monitoring$139,305
P30 · FY2011 · CA · contact PI
Clinical Research Services$390,716
P30 · FY2010 · CA · contact PI
Protocol-Specific Research Support$320,198
P30 · FY2010 · CA · contact PI
Protocol Review & Monitoring$225,289
P30 · FY2010 · CA · contact PI
Data & Safety Monitoring$152,230
P30 · FY2010 · CA · contact PI
Clinical Research Services$375,241
P30 · FY2009 · CA · contact PI
Protocol-Specific Research Support$307,516
P30 · FY2009 · CA · contact PI
Protocol Review & Monitoring$216,366
P30 · FY2009 · CA · contact PI
Data & Safety Monitoring$146,202
P30 · FY2009 · CA · contact PI
CORE-- Protocol-Specific Research Support$236,631
P30 · FY2008 · CA · contact PI
Clinical Research Services$131,835
P30 · FY2008 · CA · contact PI
Protocol-Specific Research Support$108,041
P30 · FY2008 · CA · contact PI
Protocol Review & Monitoring$76,017
P30 · FY2008 · CA · contact PI
Data & Safety Monitoring$51,366
P30 · FY2008 · CA · contact PI
CORE-- Protocol-Specific Research Support$233,313
P30 · FY2007 · CA · contact PI
Protocol Specific Research$173,327
P30 · FY2007 · CA · contact PI
Data and Safety Monitoring$138,272
P30 · FY2007 · CA · contact PI
Protocol Review and Monitoring System$55,817
P30 · FY2007 · CA · contact PI
CORE-- Protocol-Specific Research Support$126,086
P30 · FY2006 · CA · contact PI
Phase I Clinical Trials of Anticancer Agents$670,900
U01 · FY2005 · CA
CORE-- Protocol-Specific Research Support$122,414
P30 · FY2005 · CA
EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR ZD1839$12,321
M01 · FY2005 · RR
Phase I Clinical Trials of Anticancer Agents$622,307
U01 · FY2004 · CA
CORE-- Protocol-Specific Research Support$91,608
P30 · FY2004 · CA
Phase I Study of Docetaxel/Irinotecan with Celecoxib$11,587
M01 · FY2004 · RR
Paclitaxel &Carboplatin in Combination with Farnesyl$5,562
M01 · FY2004 · RR
Phase I Clinical Trials of Anticancer Agents$674,349
U01 · FY2003 · CA
PHASE I &COMPARATIVE PHARMACOKINETIC STUDY OF CONTINUOUS VENOUS INFUSION$0
M01 · FY2002 · RR
PYRAZOLOACRIDINE AND CARBOPLATIN IN PATIENTS WITH SOLID TUMORS$0
M01 · FY2002 · RR
LY231514 &GEMCITABINE EVERY 21 DAYS IN PATIENTS W/ ADVANCED CANCER$0
M01 · FY2002 · RR
SURAMIN W/ SEQUENTIAL DOXORUBICIN IN PATIENTS W/ ADVANCED SOLID TUMOR$0
M01 · FY2002 · RR
CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORS$145,313
K01 · FY2001 · CA
LY231514 &GEMCITABINE EVERY 21 DAYS IN PATIENTS W/ ADVANCED CANCER$0
M01 · FY2001 · RR
PHASE I &COMPARATIVE PHARMACOKINETIC STUDY OF CONTINUOUS VENOUS INFUSION$0
M01 · FY2001 · RR
SURAMIN W/ SEQUENTIAL DOXORUBICIN IN PATIENTS W/ ADVANCED SOLID TUMOR$0
M01 · FY2001 · RR
PYRAZOLOACRIDINE AND CARBOPLATIN IN PATIENTS WITH SOLID TUMORS$0
M01 · FY2001 · RR
CLINICAL STUDIES OF SIGNAL TRANSDUCTION INHIBITORS$140,348
K01 · FY2000 · CA
SURAMIN W/ SEQUENTIAL DOXORUBICIN IN PATIENTS W/ ADVANCED SOLID TUMOR$0
M01 · FY2000 · RR
LY231514 &GEMCITABINE EVERY 21 DAYS IN PATIENTS W/ ADVANCED CANCER$0
M01 · FY2000 · RR
PYRAZOLOACRIDINE AND CARBOPLATIN IN PATIENTS WITH SOLID TUMORS$0
M01 · FY2000 · RR
PHASE I &COMPARATIVE PHARMACOKINETIC STUDY OF CONTINUOUS VENOUS INFUSION$0
M01 · FY2000 · RR